Logo image of IBO.CA

UNIVERSAL IBOGAINE INC (IBO.CA) Stock Fundamental Analysis

TSX-V:IBO - TSX Venture Exchange - CA91360F1099 - Common Stock - Currency: CAD

0.025  0 (0%)

Fundamental Rating

0

Overall IBO gets a fundamental rating of 0 out of 10. We evaluated IBO against 0 industry peers in the Unkown industry. IBO has a bad profitability rating. Also its financial health evaluation is rather negative. IBO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IBO had negative earnings in the past year.
In the past year IBO has reported a negative cash flow from operations.
IBO.CA Yearly Net Income VS EBIT VS OCF VS FCFIBO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -60.07%
ROE -664.7%
ROIC N/A
ROA(3y)-85.01%
ROA(5y)N/A
ROE(3y)-203.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBO.CA Yearly ROA, ROE, ROICIBO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

IBO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 9.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO.CA Yearly Profit, Operating, Gross MarginsIBO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

IBO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IBO has been increased compared to 1 year ago.
The debt/assets ratio for IBO is higher compared to a year ago.
IBO.CA Yearly Shares OutstandingIBO.CA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 100M 200M 300M
IBO.CA Yearly Total Debt VS Total AssetsIBO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M

2.2 Solvency

IBO has an Altman-Z score of -9.63. This is a bad value and indicates that IBO is not financially healthy and even has some risk of bankruptcy.
IBO has a Debt/Equity ratio of 7.22. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 7.22
Debt/FCF N/A
Altman-Z -9.63
ROIC/WACCN/A
WACC7.44%
IBO.CA Yearly LT Debt VS Equity VS FCFIBO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 0.49 indicates that IBO may have some problems paying its short term obligations.
IBO has a Quick Ratio of 0.49. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
IBO.CA Yearly Current Assets VS Current LiabilitesIBO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.60% over the past year.
Looking at the last year, IBO shows a very strong growth in Revenue. The Revenue has grown by 126.31%.
EPS 1Y (TTM)29.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)126.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-36.96%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO.CA Yearly Revenue VS EstimatesIBO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO.CA Price Earnings VS Forward Price EarningsIBO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO.CA Per share dataIBO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIVERSAL IBOGAINE INC

TSX-V:IBO (5/8/2025, 7:00:00 PM)

0.025

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap7.61M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.02
P/FCF N/A
P/OCF N/A
P/B 22.28
P/tB 22.28
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.07%
ROE -664.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 9.99%
FCFM N/A
ROA(3y)-85.01%
ROA(5y)N/A
ROE(3y)-203.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 7.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.54%
Cap/Sales 2.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -9.63
F-Score3
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)60.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)15.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)126.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-36.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.58%
OCF growth 3YN/A
OCF growth 5YN/A